Concepts (65)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumopericardium | 1 | 2019 | 4 | 0.630 |
Why?
|
| Hypoxia-Ischemia, Brain | 3 | 2006 | 84 | 0.600 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2019 | 668 | 0.380 |
Why?
|
| Cerebral Palsy | 2 | 2003 | 80 | 0.370 |
Why?
|
| Chemoprevention | 1 | 2008 | 51 | 0.280 |
Why?
|
| Cystic Fibrosis | 1 | 2008 | 263 | 0.230 |
Why?
|
| Hypothermia, Induced | 1 | 2006 | 164 | 0.220 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2008 | 357 | 0.220 |
Why?
|
| Fetal Distress | 1 | 2003 | 12 | 0.210 |
Why?
|
| Antiviral Agents | 1 | 2008 | 757 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 988 | 0.190 |
Why?
|
| Infant, Newborn | 8 | 2019 | 8343 | 0.180 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2002 | 174 | 0.160 |
Why?
|
| Learning | 1 | 2002 | 357 | 0.150 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2002 | 333 | 0.140 |
Why?
|
| Palivizumab | 1 | 2008 | 46 | 0.070 |
Why?
|
| Term Birth | 1 | 2006 | 33 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2006 | 420 | 0.060 |
Why?
|
| Fetal Blood | 1 | 2006 | 171 | 0.060 |
Why?
|
| Acidosis | 1 | 2006 | 100 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 541 | 0.050 |
Why?
|
| Humans | 8 | 2019 | 126673 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2003 | 314 | 0.050 |
Why?
|
| Male | 4 | 2019 | 62489 | 0.050 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2005 | 211 | 0.050 |
Why?
|
| Pregnancy | 2 | 2006 | 7366 | 0.050 |
Why?
|
| Deafness | 1 | 2002 | 81 | 0.050 |
Why?
|
| Risk Factors | 3 | 2006 | 10545 | 0.050 |
Why?
|
| Neonatology | 1 | 2002 | 56 | 0.050 |
Why?
|
| Infant, Premature | 1 | 2005 | 823 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2003 | 1495 | 0.040 |
Why?
|
| Hospitalization | 1 | 2008 | 1874 | 0.040 |
Why?
|
| Fetal Diseases | 1 | 2003 | 454 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2002 | 408 | 0.030 |
Why?
|
| Female | 4 | 2008 | 68270 | 0.030 |
Why?
|
| Incidence | 1 | 2003 | 3247 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 2969 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2003 | 5112 | 0.030 |
Why?
|
| Heart Defects, Congenital | 1 | 2005 | 1847 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2002 | 3583 | 0.020 |
Why?
|
| Infant | 1 | 2008 | 12760 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2002 | 3262 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2002 | 2503 | 0.020 |
Why?
|
| Mutation | 1 | 2002 | 5939 | 0.020 |
Why?
|
| Animals | 1 | 2006 | 33043 | 0.010 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2005 | 161 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2005 | 306 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2005 | 354 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 2002 | 173 | 0.010 |
Why?
|
| Aminoglycosides | 1 | 2002 | 46 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2005 | 489 | 0.010 |
Why?
|
| Reoperation | 1 | 2005 | 818 | 0.010 |
Why?
|
| DNA Primers | 1 | 2002 | 602 | 0.010 |
Why?
|
| Palliative Care | 1 | 2005 | 441 | 0.010 |
Why?
|
| Haplotypes | 1 | 2002 | 525 | 0.010 |
Why?
|
| Neonatal Screening | 1 | 2002 | 190 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 781 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 2100 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 1479 | 0.010 |
Why?
|
| Alleles | 1 | 2002 | 1609 | 0.010 |
Why?
|
| DNA | 1 | 2002 | 1419 | 0.010 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2005 | 1162 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2005 | 3063 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 12537 | 0.000 |
Why?
|
| United States | 1 | 2002 | 11297 | 0.000 |
Why?
|